Personas / Equipo Humano

F. Xavier Palomer Tarridas

Buscador de publicaciones

Publicaciones

  • Palomer FX, Román-Azcona MS, Pizarro J, Planavila A, Villarroya-Gombau F, Valenzuela-Alcaraz BI, Crispi F, Sepúlveda-Martínez Á, Miguel-Escalada I, Ferrer J, Nistal JF, García R, Davidson MM, Barroso E and Vazquez M.

    SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation.

    signal transduction and targeted therapy . 5(1): 14-14. Nº de citas: 111

    [doi:10.1038/s41392-020-0114-1]

  • Zarei M, Pujol E, Quesada T, Villarroya-Gombau F, Barroso E, Vázquez S, Pizarro J, Palomer FX and Vazquez M.

    Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.

    BRITISH JOURNAL OF PHARMACOLOGY . 176(13): 2292-2305. Nº de citas: 14

    [doi:10.1111/bph.14678]

  • Zarei M, Barroso E, Palomer FX, Escolà-Gil JC, Cedó L, Wahli W and Vazquez M.

    Pharmacological PPARß/d activation upregulates VLDLR in hepatocytes.

    Clinica e Investigacion en Arteriosclerosis . 31(3): 111-118. Nº de citas: 10

    [doi:10.1016/j.arteri.2019.01.004]

  • Botteri G, Salvadó L, Gumà A, Lee Hamilton D, Meakin PJ, Montagut G, Ashford MLJ, Ceperuelo-Mallafré V, Fernández-Veledo S, Vendrell J, Calderón-Dominguez M, Serra D, Herrero L, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    The BACE1 product sAPPß induces ER stress and inflammation and impairs insulin signaling.

    METABOLISM-CLINICAL AND EXPERIMENTAL . 85: 59-75. Nº de citas: 31

    [doi:10.1016/j.metabol.2018.03.005]

  • Palomer FX, Pizarro J and Vazquez M.

    Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets?

    TRENDS IN PHARMACOLOGICAL SCIENCES . 39(5): 452-467. Nº de citas: 65

    [doi:10.1016/j.tips.2018.02.010]

  • Palomer FX, Barroso E, Pizarro J, Peña L, Botteri G, Zarei M, Aguilar D, Montori M and Vazquez M.

    PPARß/d: A Key Therapeutic Target in Metabolic Disorders.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 19(3): . Nº de citas: 73

    [doi:10.3390/ijms19030913]

  • Palomer FX, Pizarro J, Barroso E and Vazquez M.

    Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus.

    TRENDS IN ENDOCRINOLOGY AND METABOLISM . 29(3): 178-190. Nº de citas: 357

    [doi:10.1016/j.tem.2017.11.009]

  • Zarei M, Barroso E, Palomer FX, Dai J, Rada P, Quesada T, Escolà-Gil JC, Cedó L, Zali MR, Molaei M, Dabiri R, Vázquez S, Pujol E, Valverde ÁM, Villarroya-Gombau F, Liu Y, Wahli W and Vazquez M.

    Hepatic regulation of VLDL receptor by PPARß/d and FGF21 modulates non-alcoholic fatty liver disease.

    molecular metabolism . 8: 117-131. Nº de citas: 78

    [doi:10.1016/j.molmet.2017.12.008]

  • Botteri G, Montori M, Gumà A, Pizarro J, Cedó L, Escolà-Gil JC, Li D, Barroso E, Palomer FX, Kohan AB and Vazquez M.

    VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells.

    Diabetologia . 60(11): 2262-2273. Nº de citas: 29

    [doi:10.1007/s00125-017-4401-5]

  • Palomer FX, Barroso E, Zarei M, Botteri G and Vazquez M.

    PPAR beta/delta and lipid metabolism in the heart

    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS . 1861(10): 1569-1578. Nº de citas: 38

    [doi:10.1016/j.bbalip.2016.01.019]